CXCR2 and hepatocellular carcinoma: Therefore, we determined whether combined treatment of BLU-554, a highly selective, small-molecule inhibitor of FGFR4 30 and CXCL1/CXCR2 pathway inhibitors SB265610 32 had any effect on HOXB5-induced HCC metastasis.